“Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others”
The Gastroenteropancreatic Neuroendocrine Tumors market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Gastroenteropancreatic Neuroendocrine Tumors therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumors Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Gastroenteropancreatic Neuroendocrine Tumors Market by downloading the comprehensive report from DelveInsight @ Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market
Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report
The Gastroenteropancreatic Neuroendocrine Tumors Market is expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, during the forecast period [2024–2034]
The leading Gastroenteropancreatic Neuroendocrine Tumors Companies such as Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
Promising Gastroenteropancreatic Neuroendocrine Tumors Therapies such as LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others
As per DelveInsight’s assessments, the incidence of functional GEP-NET is more than that of nonfunctional GEPNET in the United States
According to Dasari et al. (2017), the incidence rate of GEP-NETs in the United States was 3.56 cases per 100,000. Incidence rates of small intestinal, rectal, and pancreatic NETs were 1.05 cases per 100,000, 1.04 cases per 100,000, and 0.48 cases per 100,000, respectively. v According to Scherubl et al. (2013), the crude incidence rate of GEP NETs in Germany rose from 0.45 cases per 100,000 in 1976 to 2.5 cases per 100,000 in 2006.
As per Masui et al. (2020), the age-adjusted overall incidence of gastro-entero-pancreatic neuroendocrineneoplasms (GEP-NEN) in Japan was 3.53 per 100,000.Most NENs in the esophagus or lungs were neuroendocrine carcinomas (NECs), while the majority of those in the duodenum, ileum, appendix and rectum were grade 1 neuroendocrine tumors (NETs).
As per Genus et al. (2019), among the 15,222 cases of NET diagnosed between 2013 and 2015, 50.7% were diagnosed with GEP-NENs, this patient cohort included both NETs and NECs, with the latter comprising 37% of all patients.
August 2024:- ITM Solucin GmbH- The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
August 2024:- RayzeBio, Inc.- Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
Gain a competitive edge in the Gastroenteropancreatic Neuroendocrine Tumors Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Gastroenteropancreatic Neuroendocrine Tumors Treatment Drugs
Gastroenteropancreatic Neuroendocrine Tumors Treatment Market
Gastroenteropancreatic Neuroendocrine Tumors treatments usually induce tumor stabilization for a limited length of time. Enormous effort is being put into developing novel approaches to overcome treatment-related resistance in patients with advanced and progressive GEP-NETs. The relatively small number of patients included in clinical studies, as well as the relatively slow course of the disease, make it difficult to evaluate the response rates for new therapies and their influence on survival.
Gastroenteropancreatic Neuroendocrine Tumors Marketed Drugs
LUTATHERA: Novartis
SOMATULINE DEPOT: Ipsen Biopharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumors Emerging Drugs
CAM2029: Camurus AB
ITM-11: ITM Isotope Technologies Munich
Discover key developments and opportunities in the Gastroenteropancreatic Neuroendocrine Tumors Market. Click here to learn more from DelveInsight’s latest report @ Gastroenteropancreatic Neuroendocrine Tumors Market Size
Gastroenteropancreatic Neuroendocrine Tumors Drugs and Companies
ITM-11: ITM Isotope Technologies Munich
CAM2029: Camurus
RYZ101: RayzeBio
Lanreotide: Merck Sharp & Dohme
arginine/lysine: Advanced Accelerator
Temozolomide (TMZ): Ipsen
Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine
RYZ101: RayzeBio, Inc.
CAM2029: Camurus AB
Everolimus: Novartis
PEN-221: Tarveda Therapeutics
Lutathera: Progenics Pharmaceuticals
Ibrutinib: Pharmacyclics
Gastroenteropancreatic Neuroendocrine Tumors Therapeutics Market
The Gastroenteropancreatic Neuroendocrine Tumors therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research activities and upcoming therapies in the forecast period [2024– 2034]
Download DelveInsight’s Gastroenteropancreatic Neuroendocrine Tumors Market report today and stay ahead in this rapidly evolving field. @ Gastroenteropancreatic Neuroendocrine Tumors Clinical Trials
Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report
Coverage- 7MM
Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limited, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc., Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, and others.
Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (Lanreotide), ITM-11, CAM2029 (Octreotide subcutaneous depot), and others.
Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumors Market Access and Reimbursement
Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors Market trends @ Gastroenteropancreatic Neuroendocrine Tumors Market Trends
Table of Content
1. Key Insights
2. Report Introduction
3. Gastroenteropancreatic Neuroendocrine Tumors Market Overview at a Glance
4. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors
5. Disease Background and Overview
6. Methodology
7. Epidemiology and Patient Population
8. Patient Journey
9. Marketed Drugs
10. Emerging Drugs
11. GEP-NET: Seven Major Market Analysis
12. KOL Views
13. SWOT Analysis
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
